Skip to main content
. Author manuscript; available in PMC: 2019 Dec 3.
Published in final edited form as: Mt Sinai J Med. 2010 Nov-Dec;77(6):655–666. doi: 10.1002/msj.20223

Table 5.

Clinical Trials With Bevacizumab in Patients With Malignant Gliomas.

Authors No. of patients Radiographic Response Rates (%) PFS (mo) OS (mo)
Stark-Vance40 21 43
Friedman et al.41 Bev alone: 85 28 4.2 9.2
Bev + CPT-11: 82 38 5.6 8.7
Kreisl et al.42 48 35 4.0
Vredenburgh et al.43 35 57

Abbreviations: Bev, bevacizumab; CPT, irinotecan; OS, overall survival; PFS, progression-free survival.